Virus News and Research

Latest Virus News and Research

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.

4 Jul 2012

Polio elimination hindered by unvaccinated children in Pakistan and Afghanistan

Too few children have received sufficient doses of vaccine to wipe out polio in Pakistan and Afghanistan, two of only three countries in the world where endemic polio has yet to be eliminated, according to new research published Online First in The Lancet. The findings suggest that the newly introduced bivalent oral poliovirus vaccine (OPV) has the potential to eliminate polio in these countries if sufficient numbers of children could be reached by vaccination programmes.

4 Jul 2012

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.

4 Jul 2012

Researcher discovers how West Nile virus breaks through the tough blood-brain barrier to CNS

Mosquitoes are buzzing once again, and with that comes the threat of West Nile virus. Tom Hobman, a researcher with the Li Ka Shing Institute of Virology in the Faculty of Medicine & Dentistry, is making every effort to put an end to this potentially serious infection.

4 Jul 2012

OraSure Technologies receives FDA approval for new in-home HIV test

The U.S. Food and Drug Administration today approved the OraQuick In-Home HIV Test, the first over-the-counter, self-administered HIV test kit to detect the presence of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2).

4 Jul 2012

Being a parent influences health in a positive way

There is no question that being a parent is, at times, challenging both physically and mentally. However knowledge of the actual affect parenthood has on health has been inconsistent at best, until now. New research led by Carnegie Mellon University's Sheldon Cohen and Rodlescia S. Sneed shows that being a parent influences health in a positive way. Published in Psychosomatic Medicine, the research provides the first evidence that, when exposed to a common cold virus, parents are 52 percent less likely to develop a cold than non-parents.

4 Jul 2012

Study to investigate costs and benefits of home-based HIV testing in Malawi

HIV remains a huge killer in Sub-Saharan Africa; especially in Malawi where up to 18% of the population is HIV positive. Early detection of the virus coupled with appropriate treatment can enormously improve both quality and length of life after diagnosis, which is why researchers at Warwick Medical School are embarking on a study to investigate the costs and benefits of home-based HIV testing in Malawi.

4 Jul 2012

Nicotine addiction: An interview with Dr. Crystal

Cigarette smoking and nicotine addiction are widespread problems throughout the world. Many people continue to smoke despite high taxes and the available public information on the dangers of smoking.

3 Jul 2012

WSU researcher looks for clues on link between H1N1 flu and obesity

The recent H1N1 flu pandemic was found to be particularly dangerous to obese people, and a Wayne State University researcher is looking for clues as to why.

3 Jul 2012

Being a parent protects against cold: Study

Being a parent reduces your risk of catching a cold—possibly because of unknown "psychological or behavioral differences between parents and nonparents," according to a study in the July issue of Psychosomatic Medicine, the official journal of the American Psychosomatic Society.

3 Jul 2012

Research highlights three factors that could determine outbreak of pandemic flu

A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.

3 Jul 2012

Gene vital to flu severity discovered

Researchers have discovered that a protein known as PA-X, produced from a ribosomal frameshift mutation in a gene in the influenza A genome, has a substantial impact on host response to the virus.

2 Jul 2012

DKK1 boosts liver cancer diagnostic options

Measurement of the protein Dickkopf-1 in serum could be used to diagnose hepatocellular carcinoma, especially early disease, Chinese researchers report.

2 Jul 2012

Safer alternative to experimental gene therapy against HIV infection

Scientists at The Scripps Research Institute have discovered a surprisingly simple and safe method to disrupt specific genes within cells. The scientists highlighted the medical potential of the new technique by demonstrating its use as a safer alternative to an experimental gene therapy against HIV infection.

2 Jul 2012

Researchers demonstrate power of single-molecule sequencing

The next "next-gen" technology in genome sequencing has gotten a major boost.

2 Jul 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

More sophisticated process needed to vet research for possible security threats

Noting that the journal Science last week published the second of two controversial bird flu research papers, in which a team led by Ron Fouchier of the Erasmus Medical Center in Rotterdam created a mutated strain of the virus that spreads easily among ferrets, a Washington Post editorial writes that "this is not the end of the story. Rather, it marks the beginning of an important chapter for both science and security."

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012